FDA Urged to Explain ANDA Deficiencies to Avoid RTR Errors
This article was originally published in The Gold Sheet
If FDA were more communicative about potential ANDA deficiencies, the agency could avoid refuse-to-receive missteps, generics firms say. Then industry wouldn’t have to challenge the many RTR decisions that are turning out to be flawed.
Register for our free email digests: